

产品名称: **Anagrelide HCl**  
 产品别名: 盐酸阿那格雷 ; **Anagrelide hydrochloride**

**生物活性:**

Description	<p>Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis. Target: PDE Anagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD). It is currently approved by the FDA as oral treatment for essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV). Anagrelide is known to inhibit platelet cyclic adenosine monophosphate (cAMP) phosphodiesterase at concentrations that exceed those achieved at doses used to treat ET. Anagrelide is extensively metabolised in the liver and its metabolites are primarily excreted in the urine [1]. Anagrelide is an established platelet-reducing drug. Studies have also investigated the effects of anagrelide on platelets, indicating that platelet function is as important as platelet counts in ET [2].</p>																	
Solvent&Solubility	<p><b>In Vitro:</b></p> <p><b>DMSO : 7.69 mg/mL (26.29 mM; Need ultrasonic)</b></p> <p><b>H2O : &lt; 0.1 mg/mL (insoluble)</b></p> <table><tr><th rowspan="3">Preparing  Stock Solutions</th><th>Solvent / Mass / Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>1 mM</th><td>3.4182 mL</td><td>17.0911 mL</td><td>34.1822 mL</td></tr><tr><th>5 mM</th><td>0.6836 mL</td><td>3.4182 mL</td><td>6.8364 mL</td></tr><tr><th>10 mM</th><td>0.3418 mL</td><td>1.7091 mL</td><td>3.4182 mL</td></tr></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <div><p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p><p>Solubility: 0.77 mg/mL (2.63 mM); Suspended solution; Need ultrasonic</p><p>此方案可获得 0.77 mg/mL (2.63 mM)的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p><p>以 1 mL 工作液为例，取 100 μL 7.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p></div> <div><p>2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline)</p><p>Solubility: 0.77 mg/mL (2.63 mM); Suspended solution; Need ultrasonic</p><p>此方案可获得 0.77 mg/mL (2.63 mM)的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p><p>以 1 mL 工作液为例，取 100 μL 7.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p></div>	Preparing  Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg	1 mM	3.4182 mL	17.0911 mL	34.1822 mL	5 mM	0.6836 mL	3.4182 mL	6.8364 mL	10 mM	0.3418 mL	1.7091 mL	3.4182 mL
	Preparing  Stock Solutions		Solvent / Mass / Concentration	1 mg	5 mg	10 mg												
			1 mM	3.4182 mL	17.0911 mL	34.1822 mL												
		5 mM	0.6836 mL	3.4182 mL	6.8364 mL													
	10 mM	0.3418 mL	1.7091 mL	3.4182 mL														

	<p>3.请依序添加每种溶剂： 10% DMSO →90% corn oil</p> <p>Solubility: <math>\geq 0.77</math> mg/mL (2.63 mM); Clear solution</p> <p>此方案可获得 <math>\geq 0.77</math> mg/mL (2.63 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 7.7 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中, 混合均匀</p>
References	<p>[1]. <u>Pescatore, S.L. and C. Lindley, Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother, 2000. 1(3): p. 537-46.</u></p> <p>[2]. <u>Petrides, P.E., Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 399-408.</u></p>



源叶生物